Aastrom Shows Off Vascular Results

Xconomy Detroit/Ann Arbor — 

Aastrom Biosciences, the Ann Arbor, MI-based developer of cell therapies for cardiovascular diseases, is presenting some new data on a clinical trial of its method against critical limb ischemia, a complication of clogged arteries that often leads to amputation and death. Detailed results from half of the first 90 patients are being presented today at the Society of Vascular Surgery meeting in Boston. Aastrom (NASDAQ: ASTM) is hosting a conference call to discuss the results today at 3:30 pm Eastern time. We profiled the company earlier this month.